July 17, 2006 -- Threshold Pharma was the disaster du jour in biotech, losing half its value after its lead drug failed a trial against prostate cancer; Lilly received FDA approval for Gemzar against ovarian cancer; Osiris set the terms for its upcoming IPO; Roche will collaborate with Actelion to develop anti-autoimmune drugs; Alnylam will speed up development in its Inex partnership; Amgen announced a follow-up trial of its kidney disease drug cinacalcet HCl; Memory achieved several milestones in its Roche partnership for neurological and psychiatric drugs; and Wyeth/Progenics received Fast Track designation for its postoperative ileus compound. The Centient Biotech 200™ fell 21 points to 3499.72, a loss of .59%. More details...
